Most chronic myeloid leukaemia (CML) patients need continuous tyrosine kinase inhibitor (TKI) therapy to maintain remission. We hypothesise that some leukaemic cells are kept in a “dormant” state, making them insensitive to TKI. This enables them to survive long-term and cause relapse if therapy ceases. We will identify and characterise these dormant cells, then use novel drugs to activate and sensitise them to TKI-mediated eradication. This would provide a new curative treatment pathway in CML.